Diagnostic and prognostic role of serum miR‐20b, miR‐17‐3p, HOTAIR, and MALAT1 in diabetic retinopathy

ABSTRACT Noncoding RNAs are emerging biomarkers for many diseases including diabetic retinopathy (DR). This study aimed to measure the expression levels of serum miR‐20b, miR‐17‐3p, HOTAIR, and MALAT1 in DR patients. A total of 80 patients diagnosed as type 2 diabetes (T2D) and 81 healthy subjects w...

Full description

Saved in:
Bibliographic Details
Published in:IUBMB life 2019-03, Vol.71 (3), p.310-320
Main Authors: Shaker, Olfat G., Abdelaleem, Omayma O., Mahmoud, Rania H., Abdelghaffar, Noha K., Ahmed, Tarek I., Said, Omar M, Zaki, Othman M.
Format: Article
Language:English
Subjects:
Adult
Biomarkers
Biomarkers - blood
Case-Control Studies
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - diagnosis
Diabetes Mellitus, Type 2 - genetics
Diabetes Mellitus, Type 2 - pathology
Diabetic retinopathy
Diabetic Retinopathy - blood
Diabetic Retinopathy - diagnosis
Diabetic Retinopathy - genetics
Diabetic Retinopathy - pathology
Early Diagnosis
Female
Gene Expression Regulation
HOTAIR
Humans
MALAT1
Male
MicroRNAs - blood
MicroRNAs - genetics
Middle Aged
miR‐17‐3p
miR‐20b
Polymerase chain reaction
Prognosis
Retinopathy
RNA, Long Noncoding - blood
RNA, Long Noncoding - genetics
ROC Curve
Severity of Illness Index
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Noncoding RNAs are emerging biomarkers for many diseases including diabetic retinopathy (DR). This study aimed to measure the expression levels of serum miR‐20b, miR‐17‐3p, HOTAIR, and MALAT1 in DR patients. A total of 80 patients diagnosed as type 2 diabetes (T2D) and 81 healthy subjects were recruited in this study. T2D patients were divided into three groups: nondiabetic retinopathy (NDR) group (30 patients), nonproliferative diabetic retinopathy (NPDR) group (30 patients), and proliferative diabetic retinopathy (PDR) group (20 patients). Quantitative real‐time polymerase chain reaction (PCR) was used to assess the expression of serum miR‐20b, miR‐17‐3p, HOTAIR, and MALAT1. We found a significant decrease in serum miR‐20b and a significant increase in serum HOTAIR and MALAT1 in NDR patients compared to healthy subjects. Also, we revealed a significant decrease in serum miR‐20b and miR‐17‐3p and a significant increase in serum HOTAIR and MALAT1 in each of NPDR and PDR groups when compared with healthy subjects. Furthermore, we reported a significant decrease in miR‐20b and miR‐17‐3p and a significant increase in HOTAIR and MALAT1in DR as well as in PDR patients when compared with NDR patients. However, on comparing NPDR with NDR patients, no significant difference was observed regarding the expression levels of miR‐20b and miR‐17‐3p, in contrast, significant elevation of serum HOTAIR and MALAT1 was found in NPDR. Moreover, we observed a significant decrease in serum miR‐20b and miR‐17‐3p and a significant increase in serum HOTAIR and MALAT1 in PDR group relative to NPDR group. Receiver operating characteristic (ROC) curve was used for evaluating the diagnostic value of the examined serum noncoding RNAs as novel biochemical indicators detecting severity of DR. Our analyses suggested that the examined serum noncoding RNAs may discriminate DR (PDR and NPDR) from NDR. Furthermore, these noncoding RNAs (less importantly miR‐17) can be used as promising novel biomarkers for prediction DR severity, distinguishing PDR from NPDR patients. We can conclude that serum miR‐20b, miR‐17‐3p, HOTAIR, and MALAT1 may be used as noninvasive biomarkers for screening of DR and early diagnosis of PDR. © 2018 IUBMB Life, 71(3):310–320, 2019
ISSN:1521-6543
1521-6551
DOI:10.1002/iub.1970